Ameliorated Pap Tests and Cervical Cancer Screening Participation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age25+
SponsorNational Taiwan University Hospital
About this trial
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.
The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
Eligibility criteria
Qualifiers
Women aged 25 or above
Disqualifiers
Ongoing menstruation
Pregnancy
Incapability of understanding the numeric pain scales
Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer)
Trial design
Treatments tested in this trial
- Modified Pap test
Treatment groups
248 Participants
are divided into 2 treatment groupsSponsors and collaborators
National Taiwan University Hospital
Lead sponsor
National Taiwan University Hospital Hsin-Chu Branch
Collaborator
National Taiwan University
Collaborator
National Taiwan University Hospital Beihu Branch
Collaborator
National Taiwan University Hospital, Yun-Lin Branch
Collaborator
National Science and Technology Council
Collaborator
Source ClinicalTrials.gov